Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415544 | 0.96 | C5AR1 (0.51) | C5AR1HTR2AHTR2CHTR2BF2R | |
| SCHEMBL5137845 | 0.95 | HTR2A (0.54) | C5AR1HTR2AHTR2CHTR2BCTSL | |
| SCHEMBL651265 | 0.93 | C5AR1 (0.53) | C5AR1HTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL5136237 | 0.93 | C5AR1 (0.55) | C5AR1HTR2AHTR2CHTR2BF2R | |
| SCHEMBL5134857 | 0.92 | C5AR1 (0.60) | C5AR1HTR2AHTR2CHTR2BF2R | |
| SCHEMBL647999 | 0.91 | C5AR1 (0.62) | C5AR1HTR2AHTR2CHTR2BF2R | |
| SCHEMBL5135110 | 0.91 | C5AR1 (0.50) | C5AR1HTR2AHTR2CHTR2BF2R | |
| SCHEMBL5137323 | 0.91 | C5AR1 (0.51) | C5AR1HTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL5134640 | 0.90 | C5AR1 (0.56) | C5AR1HTR2AHTR2CHTR2BF2R | |
| SCHEMBL5135235 | 0.89 | C5AR1 (0.54) | C5AR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |